If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
349
results.
Updated on
14/09/2026 [08:02:00]
Results 300 to 325 of 349
Absstract of: US20260207777A1
0000 Compositions and methods are provided for enhancing homology-directed repair in gene-editing applications using improved inhibitors of 53BP1.
Absstract of: US20260210974A1
Methods are provided for classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome following endovascular treatment (EVT) in an individual suffering from an acute ischemic stroke with respect to development of hemorrhagic transformation (HT). The data and integrated model provided herein demonstrates a pre-operative assessment of single-cell biomarkers for accurate prediction of HT following EVT in individuals suffering from acute ischemic strokes. The integrated model incorporates “immune features” such as activation of signaling proteins and/or the frequency of specific cell subset(s). The analysis and prediction of HT is used to guide therapeutic approaches to EVT and the post-treatment care. Specifically, the level of certain features (e.g. elevated prpS6 in memory Th1 CD4+T cells, elevated pCREB in naïve Th1 CD4+T cells and increased frequency of non-classical monocytes) demonstrate an increased likelihood of HT occurring following EVT.
Absstract of: US20260210962A1
0000 Disclosed herein are methods for detecting and treating viral infections. Disclosed is a method of detecting a virus, comprising obtaining a biological sample; capturing a plurality of membranous particles from the biological sample; measuring antigens and nucleic acid levels in the membranous particles or single virions from the biological sample; and measuring an amount of a viral RNA; wherein a virus is detected when the viral protein level or the amount of viral RNA is increased in comparison to a control sample.
Absstract of: US20260210959A1
The present disclosure relates to high density microarrays, methods of manufacturing the arrays, and uses thereof. In particular, the present disclosure provides high density microarrays of biological molecules that allow for specific and sensitive biological assays.
Absstract of: US20260210977A1
The invention relates to 5 serum peptide patterns for diagnostics of acute ischemic stroke (AIS) in humans and differential diagnosis from the intracranial hemorrhagic stroke that are defined using a list of the 100 quantitative peptides that in sera of patients with AIS are increased 2 folds or more as compared with individuals without stroke and patients with intracranial hemorrhagic stroke and a list of 54 qualitative peptides detectable in sera of the patients with AIS but not detectable in the sera of individuals without stroke and in sera of patients with intracranial hemorrhagic stroke.
Absstract of: US20260210975A1
0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.
Absstract of: US20260210961A1
0000 System and methods for identifying agents (e.g., proteins, peptides) that modulate G-protein coupled receptors (GPCRs) are generally described. For some embodiments, the agent is a nanobody that modulates the GPCR and may either act as an agonist (e.g., activate) or antagonist (e.g., deactivate) to the GPCR.
Absstract of: US20260209323A1
The present invention is concerned with single-domain antibodies directed against gasdermin D (GSDMD). The single-domain antibodies can be used in medical applications, preferably for preventing and/or treating an inflammatory disease or condition in a subject, and/or for determining the presence or absence of GSDMD oligomers in a sample obtained from a subject.
Absstract of: WO2025004009A1
The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+/- PDGFRA+/- EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.
Absstract of: SE2530023A1
0001 Abstract This invention relates to analytical chemistry, and can be used in life sciences, including medicine. It provides a method for classifying a given complex sample into prespecified subgroups. The sample is composed of a mixture of compounds and it is analyzed by a technique with resolving power insufficient for separating individual compounds. As an example, the method can be used for assessing by blood sample analysis the risk of its donor for developing or fast progression of a neurological disease caused by protein aggregation. The invention is also suitable for assessing the quality of human blood plasma stored in blood storage facilities and suitability of that plasma for transfusion or further storage.
Absstract of: CN108291916A
Provided are methods for the detection or quantization of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Abeta42) to amyloid beta 40 (Abeta40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Absstract of: WO2024229161A1
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).
Absstract of: EP4779306A1
0001 The present invention relates to organoid co-cultures and their use in the investigation of diseases. The co-culture comprises at least one organoid, at least one stromal cell, and at least one immune cell. The presence or absence of the at least one change in the co-culture is determined e.g. in response to a proinflammatory stimulus.
Absstract of: WO2025120010A1
The invention relates to a nanopore-based sensing device. In one aspect of the invention, a nanopore-based sensing device comprises at least one membrane, wherein the membrane is arranged in a way that it separates two compartments within the device, both of which are accessible by an electrode, the membrane comprising at least one nanopore comprising pneumolysin (PLY) monomers.
Absstract of: CN122427282A
本发明公开了一种靶向Gal3的抗体及其应用。所述抗体包括轻链可变区和重链可变区，其中，所述重链可变区包含氨基酸序列分别如SEQ ID NO:6、SEQ ID NO:7和SEQ ID NO:8所示的HCDR1、HCDR2和HCDR3；和/或，所述轻链可变区包含氨基酸序列分别如SEQ ID NO:10、SEQ ID NO:11和SEQ ID NO:12所示的LCDR1、LCDR2和LCDR3。本发明提供的抗体能对抑制TGF‑β/Gal3诱导的小鼠胚胎成纤维细胞NIH3T3纤维化过程，可显著改善博莱霉素诱导的小鼠呼吸功能损伤，可有效恢复阿霉素、心肌梗死和糖尿病心肌病诱导的心衰小鼠的心脏收缩功能、逆转心室异常重构进程和逆转心脏病理组织改变。
Absstract of: WO2025059015A1
Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.
Absstract of: WO2025120152A1
The present invention relates to antibodies or binding fragments thereof for use in methods of identifying or diagnosing diseases associated with extracellular trap formation or release from cells, such as Neutrophil Extracellular Trap (NET)-associated pathologies or Eosinophil Extracellular Trap (EET) -associated pathologies.
Absstract of: CN122410031A
本发明提供了美金刚在制备预防和/或治疗表达GRIN2A的小细胞肺癌的药物中的应用，属于生物医药技术领域。本发明发现GluN2A蛋白是小细胞肺癌不良预后及靶向干预的重要分子标志物。另外，本发明发现美金刚、其衍生物或药用盐能够以剂量依赖的方式显著抑制小细胞肺癌细胞的活力、克隆形成能力、DNA复制活性及迁移能力，并有效破坏3D肿瘤球体的形成、诱导肿瘤细胞死亡，显著减小了小细胞肺癌异种移植瘤的体积和重量。本发明提供的伴随诊断与靶向用药策略，克服了传统非选择性用药的盲目性，为现有小细胞肺癌的治疗提供了新的药物解决方案。
Absstract of: WO2026153209A1
A biosensing element. The biosensing element comprises: a substrate, and a thin film transistor and a reaction chamber which are located on one side of the substrate. The thin film transistor comprises: a gate, a gate insulating layer, an active layer, a source and a drain which are stacked. The thin film transistor is located in the reaction chamber, and antibodies are provided in the reaction chamber. The thin film transistor further comprises a protective layer including at least one of a first protective layer and a second protective layer, wherein the first protective layer is located between the gate insulating layer and the active layer, the second protective layer comprises a first portion that is located on the side of the part of the active layer exposed by the source and the drain away from the substrate, and a water contact angle of a material of the protective layer is greater than that of a material of the gate insulating layer.
Absstract of: WO2025014769A1
The present application provides, in some aspects, methods of assaying for β-catenin depots, and uses thereof, such as to identify a compound that modulates, such as increases, the β-catenin depots in a cell. In other aspects, also provided herein are associated methods (such as methods of identifying a compound useful for treating a β-catenin associated disease), kits, and useful compounds identified therefrom.
Absstract of: US20260199341A1
The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
Absstract of: WO2026151791A1
Provided herein are systems, kits, and methods for cell type-antigen marker (CTA marker) detection in cell samples (e.g., blood or CSF) from those suspected of having pre-clinical AD (Pre-AD) or mild cognitive impairment (MCI) or dementia from Alzheimer's Disease. In certain embodiments, such CTA marker detection is quantitative, gender specific, employs at least two gender-specific CTA markers in Figure 7C, and/or employs a mass cytometer (e.g., where mass-labeled antigen binding agents are mixed with the cell-sample). In some embodiments, at least some of the CTA markers are: i) unhealthy CTA markers which are generally upregulated in subjects with Pre-AD or MCI or dementia from Alzheimer's disease, and/or ii) healthy CTA markers which are generally down regulated in subjects with Pre-AD or MCI or Alzheimer's disease. In particular embodiments, the unhealthy CTA markers, and any healthy CTA markers employed, are used for determining a subject's risk of having or developing Pre-AD or MCI or dementia from Alzheimer's disease (e.g., by generating a score).
Absstract of: WO2026151983A1
Aspects of the disclosure relate to compositions and methods for modulating levels, transcription, splicing, and/or translation of one or more RNA transcripts (e.g., mRNA transcripts) in a cell or subject. The disclosure is based, in part, on methods of identifying a subject of having or being at risk of developing a disease or disorder associated with dysregulated glutamine levels, such as a subject having a mutation that affects glutaminase (GLS1), which is an enzyme responsible for producing glutamate from glutamine. In some embodiments, compositions and methods of the disclosure are useful for treating a psychiatric disorder (e.g., depression (DEP), major depressive disorder (MDD), bipolar disorder (e.g., BPD1, BPD2), mania (MAN), psychosis (PSY), schizophrenia (SCZ), schizoaffective disorder (SZA), or post-traumatic stress disorder (PTSD)) and/or a disease associated with dementia, such as Alzheimer's disease.
Absstract of: WO2026151932A1
The present disclosure relates to diagnosis, prognosis, and prediction of treatment outcomes of neuropathological conditions.
Nº publicación: WO2026151876A1 16/07/2026
Applicant:
HEALIX CLINICAL LABORATORY LLC [DE]
HEALIX CLINICAL LABORATORY LLC
Absstract of: WO2026151876A1
Disclosed herein are embodiments related to analyzing brain-derived extracellular vesicles (EVs). Some methods described herein comprise: (a) enriching a biological sample for brain-derived EVs, the biological sample being from a subject having a brain-related condition or disorder and comprising the brain-derived EVs; (b) subjecting the enriched sample to EV disruption to produce an analytic sample; (c) purifying the analytic sample to capture EV material after the EV disruption; and (d) analyzing the captured EV material to determine a differential amount of the captured EV material relative to a control. The method allows for improving 10 outcomes for patients suffering from brain-related conditions or disorders.
BOPI
Electronic site
